| DB00874 | Guaifenesin | Used to assist the expectoration of phlegm from the airways in acute respiratory tract infections. |
| DB01423 | Stepronin | Strepronin is a mucolytic (expectorant) drug. |
| DB04339 | Carbocisteine | Used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis. |
| DB05057 | Erdosteine | Fro the treatment of chronic bronchitis in adults. |
| DB06151 | Acetylcysteine | Acetylcysteine is used mainly as a mucolytic and in the management of paracetamol (acetaminophen) overdose. |
| DB06742 | Ambroxol | Ambroxol is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply. |
| DB08939 | Letosteine | Not Available |
| DB08990 | Eprazinone | Not Available |
| DB09019 | Bromhexine | Not Available |
| DB13163 | Terpin hydrate | Terpin hydrate is an expectorant, used in the treatment of acute and chronic bronchitis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease, infectious and inflammatory diseases of the upper respiratory tract. It is typically formulated with an antitussive (e.g., codeine) as a combined preparation. |
| DB00003 | Dornase alfa | Used as adjunct therapy in the treatment of cystic fibrosis. |
| DB00742 | Mannitol | Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances. |
| DB03852 | Eucalyptol | Not Available |
| DB06439 | Tyloxapol | Used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications. |
| DB06823 | Tiopronin | Tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization. |
| DB13293 | Ipecacuanha | Not Available |
| DB13735 | Guaiacolsulfonate | Not Available |
| DB09125 | Potassium Citrate | For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones. |